A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial

Kaoru Kubota(Nippon Medical School Hospital), Satoshi Kudoh(Japan Anti Tuberculosis Association), Hiroshi Isobe, Hironobu Ohmatsu(National Cancer Center Hospital East), Yuichi Takiguchi(Sanno Medical Center), Kunihiko Kobayashi(Saitama International Medical Center), Koichi Minato, Akira Inoue(Tohoku University Hospital), Hiroshi Sakai(Hiroshima University), Masahiro Takeuchi(The University of Tokyo), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Akira Yokoyama(Niigata Cancer Center Hospital), Yoichi Nakamura(Nagasaki University), Nobuyuki Katakami(Takarazuka City Hospital), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Minoru Fukuda(Nagasaki Prefectural Shimabara High School), Akihiko Gemma(Nippon Medical School), Hideo Kunitoh(Japanese Red Cross Medical Center), Hirofumi Michimae(Kitasato University)
Annals of Oncology
April 24, 2015
10.1093/annonc/mdv190
Cited by 89

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k